Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.

Cancer Treatment Reviews
Consuelo ButtiglieroGiorgio Vittorio Scagliotti

Abstract

In recent years, in castration resistant prostate cancer (CRPC), several new drugs have been approved that prolong overall survival, including enzalutamide and abiraterone, two new-generation hormonal therapies. Despite the demonstrated benefit of these agents, not all patients with CRPC are responsive to treatment, the gain in median progression-free survival with these therapies compared to standard of care is, rather disappointingly, still less than six months and the appearance of acquired resistance is almost universal. Approximately one third of patients treated with abiraterone and 25% of those treated with enzalutamide show primary resistance to these agents. Even if the mechanisms of resistance to these agents are not fully defined, many hypotheses are emerging, including systemic and intratumoral androgen biosynthesis up-regulation, androgen receptor (AR) gene mutations and amplifications, alteration of pathways involved in cross-talk with AR signaling, glucocorticoid receptor overexpression, neuroendocrine differentiation, immune system deregulation and others. The aim of this paper is to review currently available data about mechanisms of resistance to abiraterone and enzalutamide, and to discuss how these mechanism...Continue Reading

References

May 25, 1995·The New England Journal of Medicine·M E TaplinS P Balk
Dec 11, 1999·Cell Biochemistry and Biophysics·C T BaumannG L Hager
Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James L MohlerFrank S French
Jul 9, 2004·The Biochemical Journal·Hao Yun WongAlbert O Brinkmann
Nov 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tsutomu NishiyamaKota Takahashi
Sep 15, 2005·Chemical Reviews·Wenqing GaoJames T Dalton
Aug 3, 2006·The Journal of Clinical Endocrinology and Metabolism·Stephanie T PageWilliam J Bremner
Jun 29, 2010·Cancer Cell·Barry S TaylorWilliam L Gerald
Apr 6, 2011·Proceedings of the National Academy of Sciences of the United States of America·Houjian CaiOwen N Witte
Jun 30, 2011·Endocrine-related Cancer·Changmeng Cai, Steven P Balk
Jul 23, 2011·Endocrine-related Cancer·Scott M Dehm, Donald J Tindall
Aug 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elahe A MostaghelR Bruce Montgomery
Nov 15, 2011·The Journal of Urology·Patrick C Walsh
Nov 30, 2011·Hormones & Cancer·Saroj NiraulaAnthony Michael Joshua
Jan 24, 2012·Cancer Research·Nicola J CleggJeffrey H Hager
Mar 20, 2012·Cell·Michael S Glickman, Charles L Sawyers
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
May 24, 2013·Molecular Cancer Therapeutics·Nagalakshmi NadimintyAllen C Gao
Oct 29, 2013·Nucleic Acids Research·Charlotte SvenssonAmilcar Flores-Morales
Apr 18, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chengfei LiuAllen C Gao
Jul 23, 2014·Hormones & Cancer·Mary NakazawaJun Luo

❮ Previous
Next ❯

Citations

Nov 21, 2015·European Urology·Michael Kolinsky, Johann S de Bono
May 24, 2016·Expert Review of Anticancer Therapy·Chiara CiccareseFrancesco Massari
Jun 16, 2016·International Journal of Urology : Official Journal of the Japanese Urological Association·Yusuke Imamura, Marianne D Sadar
Jul 12, 2016·Cancers·Ida SilvestriAlessandro Sciarra
Oct 23, 2016·Drug Discovery Today. Technologies·Ester Fernandez-SalasArul M Chinnaiyan
Aug 10, 2016·Prostate Cancer and Prostatic Diseases·R R McKayM-E Taplin
Apr 7, 2018·Expert Opinion on Drug Discovery·Achuta Kumar Guddati
Oct 4, 2017·Endocrine-related Cancer·Gianmarco LeoneMassimo Di Maio
Jun 16, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Sheue-Fen TzengPei-Wen Hsiao
Jun 20, 2020·Expert Review of Anticancer Therapy·Cécile ManceauGuillaume Ploussard
Sep 1, 2018·Cell Death & Disease·Riccardo CristofaniRoberta Manuela Moretti
Feb 24, 2017·Current Oncology Reports·Mary NakazawaNatasha Kyprianou
May 6, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jieping HuTing Sun
Feb 13, 2018·Expert Opinion on Drug Metabolism & Toxicology·Jeong Hee Hong
Jan 11, 2017·Molecular Cancer Therapeutics·Jie LiXiaoqi Liu
Feb 19, 2019·Asian Journal of Urology·Liang DongKenneth J Pienta
Jan 28, 2021·Nanomaterials·Mariana MoraisRui Medeiros
Nov 21, 2020·Prostate Cancer and Prostatic Diseases·Zhengfang LiuShouzhen Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Autophagy & Metabolism

Autophagy preserves the health of cells and tissues by replacing outdated and damaged cellular components with fresh ones. In starvation, it provides an internal source of nutrients for energy generation and, thus, survival. A powerful promoter of metabolic homeostasis at both the cellular and whole-animal level, autophagy prevents degenerative diseases. It does have a downside, however--cancer cells exploit it to survive in nutrient-poor tumors.

Autophagy & Disease

Autophagy is an important cellular process for normal physiology and both elevated and decreased levels of autophagy are associated with disease. Here is the latest research.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Alzheimer's Disease: Transcription

Impaired transcription is associated with the pathogenesis and progression of conditions such as Alzheimer's disease (AD). Here are the latest discoveries pertaining to transcription and AD.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
D Lorente, J de Bono
© 2021 Meta ULC. All rights reserved